Formation Bio is rewriting the rules of drug development at a time when AI is accelerating drug discovery far faster than the industry can bring new therapies to patients. CEO Ben Liu goes Inside the ICE House to explain why the real bottleneck in pharma isn't finding promising drug candidates, it's developing them efficiently and at scale. He unpacks Formation Bio's AI-native model, which acquires already-discovered drugs and deploys proprietary tools to optimize trial design, predict clinical outcomes, and identify overlooked disease indications.
Up Next in 2026 | Inside the ICE House
-
Third Coast Bank CEO Bart Caraway on ...
Third Coast Bancshares Founder and CEO Bart Caraway joins Inside the ICE House to discuss building a Texas-based community bank from a vision into a publicly traded company now listed on the New York Stock Exchange. He reflects on launching the bank in 2008 at the onset of the Great Recession and...
-
NYSE Texas: FOA's Michael Fant on Rev...
Finance of America SVP of Finance Michael Fant joins Inside the ICE House to discuss how the company has grown into the largest originator and servicer of reverse mortgages in the United States, helping seniors tap into their home equity to fund retirement. He shares how Finance of America has sh...
-
Ginkgo Bioworks CEO Jason Kelly on En...
Ginkgo Bioworks CEO Jason Kelly joins Inside the ICE House to explain how Ginkgo is building the infrastructure to make biology programmable at scale — automating the lab work that has long bottlenecked scientific progress and offering experimentation as a cloud-based service to pharma, agricultu...
